Savant Capital LLC Purchases 63 Shares of Humana Inc. (NYSE:HUM)

Savant Capital LLC lifted its position in shares of Humana Inc. (NYSE:HUM) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,327 shares of the insurance provider’s stock after purchasing an additional 63 shares during the period. Savant Capital LLC’s holdings in Humana were worth $844,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Atlas Brown Inc. grew its position in Humana by 0.6% during the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock worth $1,611,000 after buying an additional 38 shares in the last quarter. Moors & Cabot Inc. grew its position in Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after buying an additional 40 shares in the last quarter. Mather Group LLC. grew its position in Humana by 21.0% during the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock worth $60,000 after buying an additional 41 shares in the last quarter. OLD National Bancorp IN grew its position in Humana by 1.8% during the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after buying an additional 45 shares in the last quarter. Finally, Your Advocates Ltd. LLP grew its position in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.32% of the stock is owned by corporate insiders.

Humana Stock Up 0.3 %

Shares of NYSE:HUM opened at $253.61 on Friday. The firm has a market cap of $30.54 billion, a P/E ratio of 22.46, a P/E/G ratio of 2.11 and a beta of 0.56. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The business has a fifty day simple moving average of $271.27 and a 200 day simple moving average of $294.21.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. Analysts predict that Humana Inc. will post 16.11 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on HUM. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday. TD Cowen raised their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Barclays raised their target price on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday. Wells Fargo & Company reduced their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, Morgan Stanley reduced their target price on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday. Nineteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus price target of $293.05.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.